Current academic clinical trials in ovarian cancer

Gynecologic Cancer Intergroup and US National Cancer Institute Clinical Trials Planning Meeting, May 2009.

Edward L. Trimble, Michael J. Birrer, William J. Hoskins, Christian Marth, Ray Petryshyn, Michael Quinn, Gillian M. Thomas, Henry C. Kitchener, Cancer Intergroup National Cancer Institute Writing Committee Gynecologic Cancer Intergroup National Cancer Institute Writing Committee, Carol Aghajanian, David S. Alberts, Deborah Armstrong, Jubilee Brown, Robert L. Coleman, Nicoletta Colombo, Elizabeth Eisenhauer, Michael Friedlander, Keiichi Fujiwara, Sally Hunsberger, Stan Kaye & 14 others Jonathan A. Ledermann, Susanna Lee, Katherine Look, Robert Mannel, Iain A. McNeish, Lori Minasian, Amit Oza, Jim Paul, Andres Poveda, Eric Pujade-Lauraine, Mason Schoenfeldt, Ann Marie Swart, Vivian von Gruenigen, Lari Wenzel

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

To review the current status of large phase academic clinical trials for women with ovarian cancer, address cross-cutting issues, and identify promising areas for future collaboration. In May 2009, the Gynecologic Cancer Intergroup, which represents 19 Cooperative Groups conducting trials for women with gynecologic cancer, and the US National Cancer Institute convened a Clinical Trials Planning Meeting. The topics covered included the impact of new developments in cancer biology upon molecular targets and novel agents, pharmacogenomics, advances in imaging, the potential benefit of diet and exercise to reduce the risk of recurrence, academic partnership with industry, statistical considerations for phases 2 and 3 trials, trial end points, and symptom benefit and health-related quality-of-life issues. The clinical trials discussed spanned the spectrum of ovarian cancer from initial diagnosis, staging, and cytoreductive surgery to consolidation chemotherapy, and treatment of recurrent disease. Ongoing and effective collaboration with industry, government, and patients aims to ensure that the most important scientific questions can be answered rapidly. We encourage women with ovarian cancer and their oncologists to consider participation in the academic clinical trials conducted by the member groups of the Gynecologic Cancer Intergroup.

Original languageEnglish
Pages (from-to)1290-1298
Number of pages9
JournalInternational Journal of Gynecological Cancer
Volume20
Issue number7
DOIs
Publication statusPublished - Oct 2010

Fingerprint

National Cancer Institute (U.S.)
Ovarian Neoplasms
Clinical Trials
Neoplasms
Industry
Consolidation Chemotherapy
Pharmacogenetics
Molecular Biology
Quality of Life
Exercise
Diet
Recurrence
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Current academic clinical trials in ovarian cancer : Gynecologic Cancer Intergroup and US National Cancer Institute Clinical Trials Planning Meeting, May 2009. / Trimble, Edward L.; Birrer, Michael J.; Hoskins, William J.; Marth, Christian; Petryshyn, Ray; Quinn, Michael; Thomas, Gillian M.; Kitchener, Henry C.; Gynecologic Cancer Intergroup National Cancer Institute Writing Committee, Cancer Intergroup National Cancer Institute Writing Committee; Aghajanian, Carol; Alberts, David S.; Armstrong, Deborah; Brown, Jubilee; Coleman, Robert L.; Colombo, Nicoletta; Eisenhauer, Elizabeth; Friedlander, Michael; Fujiwara, Keiichi; Hunsberger, Sally; Kaye, Stan; Ledermann, Jonathan A.; Lee, Susanna; Look, Katherine; Mannel, Robert; McNeish, Iain A.; Minasian, Lori; Oza, Amit; Paul, Jim; Poveda, Andres; Pujade-Lauraine, Eric; Schoenfeldt, Mason; Swart, Ann Marie; von Gruenigen, Vivian; Wenzel, Lari.

In: International Journal of Gynecological Cancer, Vol. 20, No. 7, 10.2010, p. 1290-1298.

Research output: Contribution to journalArticle

Trimble, EL, Birrer, MJ, Hoskins, WJ, Marth, C, Petryshyn, R, Quinn, M, Thomas, GM, Kitchener, HC, Gynecologic Cancer Intergroup National Cancer Institute Writing Committee, CINCIWC, Aghajanian, C, Alberts, DS, Armstrong, D, Brown, J, Coleman, RL, Colombo, N, Eisenhauer, E, Friedlander, M, Fujiwara, K, Hunsberger, S, Kaye, S, Ledermann, JA, Lee, S, Look, K, Mannel, R, McNeish, IA, Minasian, L, Oza, A, Paul, J, Poveda, A, Pujade-Lauraine, E, Schoenfeldt, M, Swart, AM, von Gruenigen, V & Wenzel, L 2010, 'Current academic clinical trials in ovarian cancer: Gynecologic Cancer Intergroup and US National Cancer Institute Clinical Trials Planning Meeting, May 2009.', International Journal of Gynecological Cancer, vol. 20, no. 7, pp. 1290-1298. https://doi.org/10.1111/IGC.0b013e3181ee1c01
Trimble, Edward L. ; Birrer, Michael J. ; Hoskins, William J. ; Marth, Christian ; Petryshyn, Ray ; Quinn, Michael ; Thomas, Gillian M. ; Kitchener, Henry C. ; Gynecologic Cancer Intergroup National Cancer Institute Writing Committee, Cancer Intergroup National Cancer Institute Writing Committee ; Aghajanian, Carol ; Alberts, David S. ; Armstrong, Deborah ; Brown, Jubilee ; Coleman, Robert L. ; Colombo, Nicoletta ; Eisenhauer, Elizabeth ; Friedlander, Michael ; Fujiwara, Keiichi ; Hunsberger, Sally ; Kaye, Stan ; Ledermann, Jonathan A. ; Lee, Susanna ; Look, Katherine ; Mannel, Robert ; McNeish, Iain A. ; Minasian, Lori ; Oza, Amit ; Paul, Jim ; Poveda, Andres ; Pujade-Lauraine, Eric ; Schoenfeldt, Mason ; Swart, Ann Marie ; von Gruenigen, Vivian ; Wenzel, Lari. / Current academic clinical trials in ovarian cancer : Gynecologic Cancer Intergroup and US National Cancer Institute Clinical Trials Planning Meeting, May 2009. In: International Journal of Gynecological Cancer. 2010 ; Vol. 20, No. 7. pp. 1290-1298.
@article{7a7babb84004471c8281752034b30735,
title = "Current academic clinical trials in ovarian cancer: Gynecologic Cancer Intergroup and US National Cancer Institute Clinical Trials Planning Meeting, May 2009.",
abstract = "To review the current status of large phase academic clinical trials for women with ovarian cancer, address cross-cutting issues, and identify promising areas for future collaboration. In May 2009, the Gynecologic Cancer Intergroup, which represents 19 Cooperative Groups conducting trials for women with gynecologic cancer, and the US National Cancer Institute convened a Clinical Trials Planning Meeting. The topics covered included the impact of new developments in cancer biology upon molecular targets and novel agents, pharmacogenomics, advances in imaging, the potential benefit of diet and exercise to reduce the risk of recurrence, academic partnership with industry, statistical considerations for phases 2 and 3 trials, trial end points, and symptom benefit and health-related quality-of-life issues. The clinical trials discussed spanned the spectrum of ovarian cancer from initial diagnosis, staging, and cytoreductive surgery to consolidation chemotherapy, and treatment of recurrent disease. Ongoing and effective collaboration with industry, government, and patients aims to ensure that the most important scientific questions can be answered rapidly. We encourage women with ovarian cancer and their oncologists to consider participation in the academic clinical trials conducted by the member groups of the Gynecologic Cancer Intergroup.",
author = "Trimble, {Edward L.} and Birrer, {Michael J.} and Hoskins, {William J.} and Christian Marth and Ray Petryshyn and Michael Quinn and Thomas, {Gillian M.} and Kitchener, {Henry C.} and {Gynecologic Cancer Intergroup National Cancer Institute Writing Committee}, {Cancer Intergroup National Cancer Institute Writing Committee} and Carol Aghajanian and Alberts, {David S.} and Deborah Armstrong and Jubilee Brown and Coleman, {Robert L.} and Nicoletta Colombo and Elizabeth Eisenhauer and Michael Friedlander and Keiichi Fujiwara and Sally Hunsberger and Stan Kaye and Ledermann, {Jonathan A.} and Susanna Lee and Katherine Look and Robert Mannel and McNeish, {Iain A.} and Lori Minasian and Amit Oza and Jim Paul and Andres Poveda and Eric Pujade-Lauraine and Mason Schoenfeldt and Swart, {Ann Marie} and {von Gruenigen}, Vivian and Lari Wenzel",
year = "2010",
month = "10",
doi = "10.1111/IGC.0b013e3181ee1c01",
language = "English",
volume = "20",
pages = "1290--1298",
journal = "International Journal of Gynecological Cancer",
issn = "1048-891X",
publisher = "Lippincott Williams and Wilkins",
number = "7",

}

TY - JOUR

T1 - Current academic clinical trials in ovarian cancer

T2 - Gynecologic Cancer Intergroup and US National Cancer Institute Clinical Trials Planning Meeting, May 2009.

AU - Trimble, Edward L.

AU - Birrer, Michael J.

AU - Hoskins, William J.

AU - Marth, Christian

AU - Petryshyn, Ray

AU - Quinn, Michael

AU - Thomas, Gillian M.

AU - Kitchener, Henry C.

AU - Gynecologic Cancer Intergroup National Cancer Institute Writing Committee, Cancer Intergroup National Cancer Institute Writing Committee

AU - Aghajanian, Carol

AU - Alberts, David S.

AU - Armstrong, Deborah

AU - Brown, Jubilee

AU - Coleman, Robert L.

AU - Colombo, Nicoletta

AU - Eisenhauer, Elizabeth

AU - Friedlander, Michael

AU - Fujiwara, Keiichi

AU - Hunsberger, Sally

AU - Kaye, Stan

AU - Ledermann, Jonathan A.

AU - Lee, Susanna

AU - Look, Katherine

AU - Mannel, Robert

AU - McNeish, Iain A.

AU - Minasian, Lori

AU - Oza, Amit

AU - Paul, Jim

AU - Poveda, Andres

AU - Pujade-Lauraine, Eric

AU - Schoenfeldt, Mason

AU - Swart, Ann Marie

AU - von Gruenigen, Vivian

AU - Wenzel, Lari

PY - 2010/10

Y1 - 2010/10

N2 - To review the current status of large phase academic clinical trials for women with ovarian cancer, address cross-cutting issues, and identify promising areas for future collaboration. In May 2009, the Gynecologic Cancer Intergroup, which represents 19 Cooperative Groups conducting trials for women with gynecologic cancer, and the US National Cancer Institute convened a Clinical Trials Planning Meeting. The topics covered included the impact of new developments in cancer biology upon molecular targets and novel agents, pharmacogenomics, advances in imaging, the potential benefit of diet and exercise to reduce the risk of recurrence, academic partnership with industry, statistical considerations for phases 2 and 3 trials, trial end points, and symptom benefit and health-related quality-of-life issues. The clinical trials discussed spanned the spectrum of ovarian cancer from initial diagnosis, staging, and cytoreductive surgery to consolidation chemotherapy, and treatment of recurrent disease. Ongoing and effective collaboration with industry, government, and patients aims to ensure that the most important scientific questions can be answered rapidly. We encourage women with ovarian cancer and their oncologists to consider participation in the academic clinical trials conducted by the member groups of the Gynecologic Cancer Intergroup.

AB - To review the current status of large phase academic clinical trials for women with ovarian cancer, address cross-cutting issues, and identify promising areas for future collaboration. In May 2009, the Gynecologic Cancer Intergroup, which represents 19 Cooperative Groups conducting trials for women with gynecologic cancer, and the US National Cancer Institute convened a Clinical Trials Planning Meeting. The topics covered included the impact of new developments in cancer biology upon molecular targets and novel agents, pharmacogenomics, advances in imaging, the potential benefit of diet and exercise to reduce the risk of recurrence, academic partnership with industry, statistical considerations for phases 2 and 3 trials, trial end points, and symptom benefit and health-related quality-of-life issues. The clinical trials discussed spanned the spectrum of ovarian cancer from initial diagnosis, staging, and cytoreductive surgery to consolidation chemotherapy, and treatment of recurrent disease. Ongoing and effective collaboration with industry, government, and patients aims to ensure that the most important scientific questions can be answered rapidly. We encourage women with ovarian cancer and their oncologists to consider participation in the academic clinical trials conducted by the member groups of the Gynecologic Cancer Intergroup.

UR - http://www.scopus.com/inward/record.url?scp=79952667176&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952667176&partnerID=8YFLogxK

U2 - 10.1111/IGC.0b013e3181ee1c01

DO - 10.1111/IGC.0b013e3181ee1c01

M3 - Article

VL - 20

SP - 1290

EP - 1298

JO - International Journal of Gynecological Cancer

JF - International Journal of Gynecological Cancer

SN - 1048-891X

IS - 7

ER -